AlloVir (ALVR) Stock Forecast & Price Target $0.82 -0.01 (-1.21%) (As of 10/3/2024 ET) Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends AlloVir - Analysts' Recommendations and Stock Price Forecast (2024) How MarketBeat Calculates Price Target and Consensus Rating MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Consensus Rating ReduceBased on 5 Analyst RatingsSell2Hold3Buy0 Based on 5 Wall Street analysts who have issued ratings for AlloVir in the last 12 months, the stock has a consensus rating of "Reduce." Out of the 5 analysts, 2 have given a sell rating, and 3 have given a hold rating for ALVR. Consensus Price Target N/A Get the Latest News and Ratings for ALVR and Related Stocks Enter your email address to receive the latest news and analysts' ratings for AlloVir and its competitors. Enter your email to sign up for newsletter Sign Up ALVR Analyst Ratings Over TimeTypeCurrent Forecast10/5/23 to 10/4/241 Month Ago9/5/23 to 9/4/243 Months Ago7/7/23 to 7/6/241 Year Ago10/5/22 to 10/5/23Strong Buy0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)Buy0 Buy rating(s)0 Buy rating(s)1 Buy rating(s)3 Buy rating(s)Hold3 Hold rating(s)3 Hold rating(s)3 Hold rating(s)0 Hold rating(s)Sell2 Sell rating(s)2 Sell rating(s)2 Sell rating(s)0 Sell rating(s)Consensus Price TargetN/AN/A$18.50$18.75Forecasted UpsideN/AN/A2,542.48% Upside797.13% UpsideConsensus RatingReduceReduceReduceBuy “A very dark day is coming to America” (Ad)Wall Street Legend on Economy: "If you knew what I know, you'd be terrified too." Something huge is headed to America's shores – and it scares the hell out of Wall St. legend Louis Navellier. When it makes landfall, its impact will be more violent and more severe than any financial crisis we've ever seen… "No matter how prepared you think you are, you aren't prepared enough," he warns.Click here to see his official warning. ALVR Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History ALVR Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table AlloVir Stock vs. The CompetitionTypeAlloVirMedical CompaniesS&P 500Consensus Rating Score 1.60 2.78 2.50Consensus RatingReduceModerate BuyHoldPredicted UpsideN/A850.27% Upside7.73% UpsideNews Sentiment RatingPositive NewsSee Recent ALVR NewsPositive NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export to Excel DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails12/26/2023Bank of America4 of 5 stars DowngradeBuy ➝ Underperform12/22/2023Leerink Partnrs0 of 5 starsM. ForooharSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform12/22/2023Leerink Partners1 of 5 stars DowngradeOutperform ➝ Market Perform12/22/2023Piper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy rating DowngradeOverweight ➝ Neutral12/22/2023JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy rating DowngradeOverweight ➝ Underweight8/7/2023Morgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy rating Reiterated RatingOverweight ➝ Overweight$20.00+575.67%4/26/2023SVB SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy rating Boost Target$16.00 ➝ $19.00+420.55%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 03:39 AM ET. ALVR Forecast - Frequently Asked Questions Should I buy or sell AlloVir stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AlloVir in the last twelve months. There are currently 2 sell ratings and 3 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" ALVR shares. Does AlloVir's stock price have much downside? According to analysts, AlloVir's stock has a predicted downside of -100.00% based on their 12-month stock forecasts. Do Wall Street analysts like AlloVir more than its competitors? Analysts like AlloVir less than other "medical" companies. The consensus rating for AlloVir is Reduce while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ALVR compares to other companies. Stock Forecasts and Research Tools Related Companies: BLUE Stock Forecast ATRA Stock Forecast CGC Stock Forecast ALVO Stock Forecast ZVRA Stock Forecast SNDL Stock Forecast VYGR Stock Forecast JSPR Stock Forecast KRRO Stock Forecast CRVS Stock Forecast Today's Ratings: U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top Rated Stocks: Top Rated Stocks Top Rated Dividend Stocks Top Rated Small-Cap Stocks Top Rated Tech Stocks Most Upgraded Stocks Most Downgraded Stocks Lowest Rated Stocks More Ratings Tools: Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Next opportunity for crypto millions (Ad)The floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since they first opened to investors. Wall Street is finally embracing crypto. But most investors are missing the real goldmine… Go here to discover the crypto that's about to leave Wall Street in the dust. This page (NASDAQ:ALVR) was last updated on 10/4/2024 by MarketBeat.com Staff From Our PartnersThe world’s smartest man is in their crosshairsElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | SponsoredTrade Alongside Pelosi, Buffett, and MorePeople don't know that you can trade alongside politicians, lawmakers, and top investors like Warren Buffet, B...Bullseye Trades | SponsoredKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppe...Paradigm Press | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredAI expert reveals new Nvidia predictionEveryone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released...Brownstone Research | SponsoredMassive NVIDIA Sell-Off: Are We Headed for a Market Collapse?You may have heard about NVIDIA's CEO dumping shares of his own company. He sold 4.4 million shares this ye...Behind the Markets | SponsoredNext opportunity for crypto millionsAll the Pieces Falling into Place for Crypto… Unlock the Potential of the 2024 Crypto Bull Run!Crypto 101 Media | SponsoredWho are Nvidia’s New Silent Partners?Nvidia knows it can’t stand still as AI continues to grow at an exponential rate. That’s why CEO Jensen Hua...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AlloVir, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AlloVir With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.